Akebia Therapeutics (AX9) Income Statement
Akebia Therapeutics Income Statement
Last quarter (Q2 2026), Akebia Therapeutics's total revenue was $49.13M, a decrease of 21.36% from the same quarter last year. In Q2, Akebia Therapeutics's net income was $-8.91M. See Akebia Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 236.20M | $ 160.18M | $ 194.62M | $ 292.48M | $ 211.65M | |
| $ 196.73M | $ 97.00M | $ 120.47M | $ 269.99M | $ 130.16M | |
| $ 173.24M | $ 147.47M | $ 166.73M | $ 350.77M | $ 394.66M | |
| Depreciation and Amortization | $ 1.27M | $ 37.50M | $ 37.63M | $ 37.70M | $ 37.97M |
| $ 21.73M | $ -13.72M | $ -8.27M | $ 3.06M | $ -189.91M | |
| $ 23.50M | $ -50.47M | $ -46.26M | $ -80.78M | $ -264.50M | |
| $ -27.22M | $ -18.94M | $ -5.67M | $ -13.45M | $ -17.52M | |
| $ -3.72M | $ -69.41M | $ -51.92M | $ -94.23M | $ -282.02M | |
| $ -5.34M | $ -69.41M | $ -51.92M | $ -94.23M | $ -282.02M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.02 | $ -0.33 | $ -0.28 | $ -0.58 | $ -1.48 |
| Diluted EPS | $ -0.02 | $ -0.33 | $ -0.28 | $ -0.58 | $ -1.48 |
| Weighted Average Shares Outstanding | 257.16M | 210.95M | 187.47M | 182.78M | 165.95M |
| Weighted Average Shares Outstanding (Diluted) | 257.16M | 210.95M | 187.47M | 182.78M | 165.95M |
Currency in USD
